References
- 1. S. Negoro, N. Masuda, Y. Takada, T. Sugiura, S. Kudoh, N. Katakami, Y. Ariyoshi, Y. Ohashi, H. Nittani and M. Fukuoka, Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer, Br. J. Cancer.88 (2003) 335–341; https://doi.org/10.1038/sj.bjc.6600725
- 2. Y. Takahashi, H. Kitakata, K. Yamashita, K. Yasumoto, K. Omote, T. Minamoto and M. Mai, Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer, Surg. Today34 (2004) 246–250; https://doi.org/10.1007/s00595-003-2688-y
- 3. M. J. Hageman and W. Morozowich, Case Study: Irinotecan (CPT-11), a Water-Soluble Prodrug of SN-38, in Prodrugs: Challenges and Rewards – Part 1 (Eds. V. J. Stella, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag and J. W. Tilley), Berlin 2007, pp. 1269–1279 (Book Series: Biotechnology: Pharmaceutical Aspects)
- 4. L. P. Rivory, Irinotecan (CPT-11): A brief overview, Clin. Exp. Pharmacol. Physiol.23 (1996) 1000–1004.
- 5. H. Wei, J. Song, H. Li, Y. Li, S. Zhu, X. Zhou, X. Zhang and L. Yang, Active loading liposomal irinotecan hydrochloride: Preparation, in vitro and in vivo evaluation, Asian J. Pharm. Sci.8 (2013) 303–311; https://doi.org/10.1016/j.ajps.2013.10.006
- 6. N. Taneja, V. Gota, M. Gurjar and K. K. Singh, Development and validation of high-performance liquid chromatographic method for quantification of irinotecan and its active metabolite SN-38 in colon tumor bearing NOD/SCID mice plasma samples: Application to pharmacokinetic study, Acta Chromatogr.31 (2019) 166–172; https://doi.org/10.1556/1326.2018.00370
- 7. E. Gravel, P. Bourget, L. Mercier and A. Paci, Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: Application to camptothecin derivatives, J. Pharm. Biomed. Anal.39 (2005) 581–586; https://doi.org/10.1016/j.jpba.2005.05.010
- 8. S. Poujol, F. Pinguet, F. Malosse, C. Astre, M. Ychou, S. Culine and F. Bressolle, Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies, Clin. Chem.49 (2003) 1900–1908; https://doi.org/10.1373/clinchem.2003.023481
- 9. T. S. Owens, H. Dodds, K. Fricke, S. K. Hanna and K. R. Crews, High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma, J. Chromatogr. B788 (2003) 65–74; https://doi.org/10.1016/S1570-0232(02)01016-4
- 10. S. Bardin, W. Guo, J. L. Johnson, S. Khan, A. Ahmad, J. X. Duggan, J. Ayoub and I. Ahmad, Liquid chromatographic–tandem mass spectrometric assay for the simultaneous quantification of Camptosar® and its metabolite SN-38 in mouse plasma and tissues, J. Chromatogr. A1073 (2005) 249–255; https://doi.org/10.1016/j.chroma.2004.08.060
- 11. M. I. Rodríguez Cáceres, I. Durán-Merás, N. E. O. Soto, P. L. L. de Alba and L. L. Martínez, Spec-trofluorimetric determination of irinotecan in the presence of oxidant agents and metal ions, Talanta74 (2008) 1484–1491; https://doi.org/10.1016/j.talanta.2007.09.025
- 12. M. Tariq, L. M. Negi, S. Talegaonkar, F. J. Ahmad, Z. Iqbal and A. M. Khan, Liquid chromatographic method for irinotecan estimation: Screening of P-gp modulators, Indian J. Pharm. Sci.77 (2015) 14–23; https://doi.org/10.4103/0250-474X.151577
- 13. P. Shende and R. Gaud, Validated RP-HPLC analysis of irinotecan HCl in the bulk material and in pharmaceutical formulations, Acta Chromatogr.21 (2009) 71–82; https://doi.org/10.1556/AChrom.21.2009.1.6
- 14. T. Xuan, J. A. Zhang and I. Ahmad, HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38, J. Pharm. Biomed. Anal.41 (2006) 582–588; https://doi.org/10.1016/j.jpba.2005.10.051
- 15. L. Kumar, M. S. Reddy, R. S. Managuli and K. G. Pai, Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles, Saudi Pharm. J.23 (2015) 549–555; https://doi.org/10.1016/j.jsps.2015.02.001
- 16. R. S. Managuli, L. Kumar, A. D. Chonkar, R. K. Shirodkar, S. Lewis, K. B. Koteshwara, M. S. Reddy and S. Mutalik, Development and validation of a stability-indicating RP-HPLC method by a statistical optimization process for the quantification of asenapine maleate in lipidic nanoformulations, J. Chromatogr. Sci.54 (2016) 1290–1300; https://doi.org/10.1093/chromsci/bmw062
- 17. M. S. Reddy, L. Kumar, Z. Attari and R. Verma, Statistical optimization of extraction process for the quantification of valsartan in rabbit plasma by a HPLC method, Indian J. Pharm. Sci.79 (2017) 16–28; https://doi.org/10.4172/pharmaceutical-sciences.1000196
- 18. J. Shao, W. Cao, H. Qu, J. Pan and X. Gong, A novel quality by design approach for developing an HPLC method to analyze herbal extracts: A case study of sugar content analysis, PLoS One13 (2018) e0198515 (15 pages); https://doi.org/10.1371/journal.pone.0198515
- 19. A. H. Schmidt and I. Molnár, Using an innovative quality-by-design approach for development of a stability indicating UHPLC method for ebastine in the API and pharmaceutical formulations, J. Pharm. Biomed. Anal.78–79 (2013) 65–74; https://doi.org/10.1016/j.jpba.2013.01.032
- 20. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Geneva, November 2005; https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access March 20, 2019
- 21. J. J. Kirkland, M. A. van Straten and H. A. Claessens, High pH mobile phase effects on silica-based reversed-phase high-performance liquid chromatographic columns, J. Chromatogr. A.691 (1995) 3–19; https://doi.org/10.1016/0021-9673(94)00631-I
- 22. R. Khurana, S. Beg, D. Lal, O. P. Katare and B. Singh, Analytical quality by design approach for development of a validated bioanalytical UPLC method of docetaxel trihydrate, Curr. Pharm. Anal.11 (2015) 180–192; https://doi.org/10.2174/1573412911666150121234150
- 23. M. Herneisey, L. Liu, E. Lambert, N. Schmitz, S. Loftus and J. M. Janjic, Development of theranostic perfluorocarbon nanoemulsions as a model non-opioid pain nanomedicine using a Quality by Design (QbD) approach, AAPS PharmSciTech20 (2019) Article ID 65; https://doi.org/10.1208/s12249-018-1287-6
- 24. J. Dolan, A Guide to HPLC and LC-MS Buffer Selection. ACE HPLC Columns – Ultra Inert Base-Deactivated HPLC Columns, Advanced Chromatogrpahy Technologies, Aberdeen; https://www.hplc.eu/Downloads/ACE_Guide_BufferSelection.pdf; last access April 5, 2019.
- 25. A. Bozkir and O. M. Saka, Formulation and investigation of 5-FU nanoparticles with factorial design-based studies, Farmaco60 (2005) 840–846; https://doi.org/10.1016/j.farmac.2005.06.016
- 26. Indian Pharmacopoeia 2007, Government of Indian, Ministry of Health & Family Welfare, The Indian Pharmacopoeia Commission, Ghaziabad 2007.